Live Online Event

October 26-28, 2020 – Internal Medicine: An Evidence-Based Approach to Endocrinology and Rheumatology

Title:October 26-28, 2020 – Internal Medicine: An Evidence-Based Approach to Endocrinology and Rheumatology
Dates:October 26, 2020 7:30 am - October 28, 2020 12:50 pm
Location:Online
Schedule:7:30am-12:50pm
Course #:SEMLA-webinar-im-10262020

Certifications

15 AMA PRA Category 1 Credits™

15 AAFP Credits

Course Outline

Day 1

Evaluation of the Patient with Musculoskeletal Complaints. 

Upon completion of this session, the participant should be able to: COMP

  1. Recognize the symptoms of an inflammatory arthritis versus osteoarthritis
  2. List the pattern of joint involvement in the various types of arthritis
  3. Utilize lab tests to aid in diagnosing the various forms of arthritis
  4. Describe the typical x-ray findings in the common forms of arthritis

Rheumatoid Arthritis.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Describe the immunologic abnormalities, genetic and environmental factors, and synovial changes occurring in rheumatoid arthritis
  2. Recognize the articular and extra articular manifestations of rheumatoid arthritis
  3. Use the ACR classification criteria to confirm the diagnosis of RA
  4. Choose and monitor the appropriate treatment for RA according the ACR guidelines

Prevention of Type 2 Diabetes/Treatment of Obesity.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Recognize patients with pre-diabetes.
  2. Employ current Guidelines and recommendations regarding diabetes prevention.
  3. Describe properties of currently available medications for obesity, their adverse effect profile, and how to incorporate them as part of an effective obesity treatment program.

Treatment of Hyperglycemia in Type 2 Diabetes (Non-Insulin)

Upon completion of this session, the participant should be able to: EBM, GL, COMP

  1. Understand the glucose targets in T2DM.
  2. Employ the current ADA Guidelines for pharmacological therapy.
  3. Develop individualized therapeutic regimens to optimize glycemic control.

Treatment of Hyperglycemia in Type 2 Diabetes (Insulin)

Upon completion of this session, the participant should be able to: EBM, GL, COMP

  1. Recognize indications for the initiation of insulin replacement therapy for people with T2DM.
  2. Describe clinically relevant properties of the available insulins and insulin combinations.
  3. Individualize and advance insulin therapy to optimize glycemic control.

Day 2

Spondylarthritis.

Upon completion of this session, the participant should be able to: GL, EBM. COMP

  1. Recognize the common and overlapping as well as the distinguishing clinical findings of the various types of spondyloarthritis
  2. Describe the unique clinical radiographic features of spondyloarthritis
  3. Explain the role of HLA-B27 testing in the evaluation of patients with possible axial spondyloarthritis
  4. Apply the ACR/EULAR recommendations for evidence-based treatment of spondyloarthritis

Systemic Lupus Erythematosus.

Upon completion of this session, the participant should be able to: GL, EBM. COMP

  1. Recognize the common as well as the less frequent clinical and laboratory manifestations of SLE
  2. Use laboratory testing to help confirm the diagnosis and monitor the activity of SLE
  3. Apply the 2019 ACR/EULAR diagnostic criteria to diagnose a patient with SLE
  4. Use the 2019 EULAR treatment guidelines for evidence-based treatment of SLE

Raynaud’s, Scleroderma and the Inflammatory Myopathies.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Describe the evaluation of a patient presenting with and treatment of Raynaud’s
  2. Initiate an evaluation of patient and diagnosis of systemic sclerosis based on the 2013 ACR/EULAR classification of systemic sclerosis
  3. Recognize the involvement of internal organs associated with systemic sclerosis
  4. Identify patients with Idiopathic Inflammatory Myopathies using the 2017 EULAR/ACR classification criteria

Thyroid Disease

Upon completion of this session, the participant should be able to: GL, EBM. COMP

  1. Individualize evaluation and management options for
  2. Review evaluation and treatment options for hyperthyroidism.
  3. Review current guidelines describing the evaluation and management of thyroid nodules.

Common Endocrine Disorders.

Upon completion of this session, the participant should be able to: EBM, GL, COMP

  1. Recognize, evaluate and treat common endocrine abnormalities and employ Endo Society Guidelines to include:
    1. Hypoglycemia,
    2. Hypercalcemia,
    3. Low testosterone,
    4. Adrenal masses.

Day 3

Polymyalgia Rheumatica and Giant Cell Arteritis.

Upon completion of this session, the participant should be able to: EBM. COMP

  1. Describe the typical symptoms, physical findings, and laboratory abnormalities in polymyalgia rheumatica
  2. Use evidence-based information to determine the appropriate initial dose of prednisone for patients with PMR
  3. Detect the typical and atypical presentations of GCA
  4. Determine the appropriate indication and technique for temporal artery biopsy

Gout and Pseudogout.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Recognize the typical and atypical presentations of gouty arthritis
  2. Develop a treatment plan based on the ACR treatment guidelines for the treatment of gout
  3. Determine the clinical manifestations of calcium pyrophosphate deposition disease
  4. Differentiate the polarized microscopic findings for uric acid and CPPD crystals

Diabetes Technology.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Discuss new trends and hot topics in diabetes technology.
  2. Recognize and identify clinical scenarios where the use of newer technology, such as insulin pumps and/or continuous glucose monitors, may be indicated to support insulin replacement therapy
  3. Discuss how new technologies, such as insulin pumps and continuous glucose monitors, are incorporated into routine practice.
  4. Describe potential risks and benefits of available nonprescription diabetes management technologies

Transgender Care.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Identify the differences between sex, gender identity, sexual preference and gender expression and be able to use the appropriate terminology.
  2. Describe how to safely and effectively utilize masculinizing and feminizing hormonal treatments for appropriate patients.
  3. Assess the components of, expected changes, time line and outcomes of cross hormone therapy.

Common Cases Walking Through Your Office Door.

Clinical Cases will be solicited throughout the week from the participants.  These cases will be selected and managed by the presenters. Diagnoses, next steps in management and expected clinical outcomes will be discussed.  The format will include panel discussion and audience participation.

Presented By

Presenter

  • Merri Lou Pendergrass, M.D., Ph.D. (Learn More)
    Professor of Medicine, Clinical Chief of Endocrinology, and Director of the Diabetes Program, University of Arizona College of Medicine, Tucson, AZ
  • John W. Pendleton, M.D., F.A.C.P., F.A.C.R. (Learn More)
    Associate Professor of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA

Register

You need to buy a ticket to register for this webinar. Click here to buy a ticket.

Need help? Have a question?

mail@ams4cme.com 1-866-267-4263 Disclaimer: AMS reserves the right to cancel any conference within 6 weeks of conference date. Registrants will receive a full refund within 7 business days. AMS is not responsible for charges associated with canceled flight or hotel rooms. AMS Cancellation Policy: Due to COVID-19, American Medical Seminars has implemented a Worry-Free Cancellation policy. Register for our Live Events with the peace of mind knowing you can cancel at anytime, penalty free. If you are an international attendee and need to cancel the seminar after an Invitation Letter has been sent, there is a $150.00 cancellation fee.